136 related articles for article (PubMed ID: 37500172)
21. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
Lundberg IV; Edin S; Eklöf V; Öberg Å; Palmqvist R; Wikberg ML
BMC Cancer; 2016 Jul; 16():471. PubMed ID: 27411517
[TBL] [Abstract][Full Text] [Related]
22. Loss of
Caldas ÁMC; Nunes WA; Taboada R; Cesca MG; Germano JN; Riechelmann RP
Ecancermedicalscience; 2024; 18():1666. PubMed ID: 38439814
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-9-5p-CDX2 Axis: A Useful Prognostic Biomarker for Patients with Stage II/III Colorectal Cancer.
Nishiuchi A; Hisamori S; Sakaguchi M; Fukuyama K; Hoshino N; Itatani Y; Honma S; Maekawa H; Nishigori T; Tsunoda S; Obama K; Miyoshi H; Shimono Y; Taketo MM; Sakai Y
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31783700
[TBL] [Abstract][Full Text] [Related]
24. Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients.
Aasebø K; Bruun J; Bergsland CH; Nunes L; Eide GE; Pfeiffer P; Dahl O; Glimelius B; Lothe RA; Sorbye H
Br J Cancer; 2022 Jan; 126(1):48-56. PubMed ID: 34671130
[TBL] [Abstract][Full Text] [Related]
25. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma.
Slik K; Turkki R; Carpén O; Kurki S; Korkeila E; Sundström J; Pellinen T
Am J Surg Pathol; 2019 Nov; 43(11):1473-1482. PubMed ID: 31490234
[TBL] [Abstract][Full Text] [Related]
26. JARID1B promotes colorectal cancer proliferation and Wnt/β-catenin signaling via decreasing CDX2 level.
Huang D; Xiao F; Hao H; Hua F; Luo Z; Huang Z; Li Q; Chen S; Cheng X; Zhang X; Fang W; Hu X; Liu F
Cell Commun Signal; 2020 Oct; 18(1):169. PubMed ID: 33109187
[TBL] [Abstract][Full Text] [Related]
27. ARE CDX2, BETA-CATENIN AND WNT IMMUNOMARCHERS USEFUL FOR EVALUATING THE CHANCE OF DISEASE PROGRESSION OR EVOLUTION TO DEATH IN PATIENTS WITH COLORECTAL CANCER?
Bremer FP; Czeczko NG; CollaÇo LM; Rutz LEAC; Gionedis G; Yamakawa CK
Arq Bras Cir Dig; 2020; 33(3):e1534. PubMed ID: 33331430
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Cremolini C; Lonardi S; Okazaki S; Berger MD; Miyamoto Y; Soni S; Barzi A; Yamaguchi T; Loupakis F; Falcone A; Lenz HJ
Pharmacogenomics J; 2021 Jun; 21(3):285-295. PubMed ID: 33542444
[TBL] [Abstract][Full Text] [Related]
29. Double Negativity for Expression of YAP1 and CDX2 Defines an Aggressive Type of Colitis-associated Cancer.
Yin F; Xie H; Lai J; Chen Y; Dong J; Zhang X; Liu X
Anticancer Res; 2020 Oct; 40(10):5411-5416. PubMed ID: 32988861
[TBL] [Abstract][Full Text] [Related]
30. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.
Bae JM; Lee TH; Cho NY; Kim TY; Kang GH
World J Gastroenterol; 2015 Feb; 21(5):1457-67. PubMed ID: 25663765
[TBL] [Abstract][Full Text] [Related]
31. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.
Dabir PD; Svanholm H; Christiansen JJ
APMIS; 2018 Jun; 126(6):494-500. PubMed ID: 29924451
[TBL] [Abstract][Full Text] [Related]
32. Potential predictors for CDX2 expression loss and mismatch repair deficiency in colorectal cancer.
Vlahović I; Rajc J; Švagelj I; Šolić K; Švagelj D
Pathol Oncol Res; 2023; 29():1610908. PubMed ID: 37325467
[TBL] [Abstract][Full Text] [Related]
33. CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway.
Graule J; Uth K; Fischer E; Centeno I; Galván JA; Eichmann M; Rau TT; Langer R; Dawson H; Nitsche U; Traeger P; Berger MD; Schnüriger B; Hädrich M; Studer P; Inderbitzin D; Lugli A; Tschan MP; Zlobec I
Clin Epigenetics; 2018 Sep; 10(1):120. PubMed ID: 30257705
[TBL] [Abstract][Full Text] [Related]
34. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
35. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of CDX2 and Villin Expression in Advanced Stage Colorectal Carcinoma.
Altintas S; Bayrak M; Altintas Y
J Coll Physicians Surg Pak; 2019 Nov; 29(11):1057-1061. PubMed ID: 31659962
[TBL] [Abstract][Full Text] [Related]
37. A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma.
Wong NACS; Adamczyk LA; Evans S; Cullen J; Oniscu A; Oien KA
Histopathology; 2017 Jul; 71(1):34-41. PubMed ID: 28226180
[TBL] [Abstract][Full Text] [Related]
38. Altered expression of CDX2 in colorectal cancers.
Choi BJ; Kim CJ; Cho YG; Song JH; Kim SY; Nam SW; Lee SH; Yoo NJ; Lee JY; Park WS
APMIS; 2006 Jan; 114(1):50-4. PubMed ID: 16499661
[TBL] [Abstract][Full Text] [Related]
39. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status.
Lugli A; Tzankov A; Zlobec I; Terracciano LM
Mod Pathol; 2008 Nov; 21(11):1403-12. PubMed ID: 18587323
[TBL] [Abstract][Full Text] [Related]
40. Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer.
Tarazona N; Gimeno-Valiente F; Gambardella V; Huerta M; Roselló S; Zuniga S; Calon A; Carbonell-Asins JA; Fontana E; Martinez-Ciarpaglini C; Eason K; Rentero-Garrido P; Fleitas T; Papaccio F; Moro-Valdezate D; Nyamundanda G; Castillo J; Espí A; Sadanandam A; Roda D; Cervantes A
ESMO Open; 2020 Sep; 5(5):e000847. PubMed ID: 32967918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
